Navigation Links
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago.  Data being presented include the results from two clinical trials evaluating the safety and efficacy of ABT-199, a BCL-2 selective inhibitor, in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).

Meeting abstracts are available today at http://chicago2013.asco.org/abstracts.

"These presentations further solidify our commitment to addressing the unmet need for new therapies that can improve on current treatment options for patients with cancer," said Gary Gordon , M.D., divisional vice president, oncology clinical development, AbbVie. "With our pioneering research, we are breaking new ground in some of the most widespread and difficult-to-treat cancers."

Presentation Details:

ABT-199

  • Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL); J.F. Seymour , et al.; Abstract 7018; Poster Discussion Session; June 1, 2013; 8:00 a.m.-12:00 p.m.
  • Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) non-Hodgkin's Lymphoma (NHL); M.S. Davids , et al.; Abstract 8520; Oral Presentation; June 3, 2013; 11:30 a.m.-1:30 p.m.

Elotuzumab

  • A Phase
    '/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
2. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
3. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
4. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
5. AbbVie Reports First-Quarter 2013 Financial Results
6. AbbVie to Host First-Quarter Earnings Conference Call
7. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
8. AbbVie to Present at Barclays Global Health Care Conference
9. AbbVie Issues Inaugural Full-Year Outlook for 2013
10. AbbVie Named to S&P 500 Dividend Aristocrat Index
11. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015 Jintian Pharmaceutical Group Limited ("Jintian ... Mr. Jin Dongtao, chairman and executive director purchased 40,000,000 ... of the existing entire issued share capital of the ... with the total amount of approximately HK$113 million. Upon ... will increase from 45.17% to 47.17%. ...
(Date:4/1/2015)... 1, 2015  For many businesses and industries just ... the case, having the right management software can be ... better than software solutions company TraxStar Technologies , ... the company announced the release of the newest version ... "QATrax ...
(Date:4/1/2015)... WAYNE, Pa. , April 1, 2015 /PRNewswire/ ... fully integrated specialty pharmaceutical company focused on developing, ... the pricing of an offering of $60.0 million ... due 2020 (the "notes") in a private placement ... under the Securities Act of 1933, as amended ...
Breaking Medicine Technology:Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7
... , FRANKLIN LAKES, N.J., Dec. 29 ... matrix engineering, announced today that Dr. Shu-Tung Li, the ... as New Jersey,s 2009 Executive of the Year, an ... and Mattia, Certified Public Accountants and Consultants. In ...
... , , , , ... developer of medical device technology for the safe handling, ... Webinar program supporting its culture of safety initiative for ... Culture of Safety in Pharmacy: Lessons Learned," features an ...
Cached Medicine Technology:Shu-Tung Li, Founder and CEO of Collagen Matrix, Inc. Honored as 2009 New Jersey Executive of the Year and Company Named Sixteenth Fastest Growing Company 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 3
(Date:4/1/2015)... Tempaper has joined forces with the Muscular ... that will raise critical funds to help save and ... the United States. , Throughout the month of April, ... will automatically receive free domestic ground shipping on all ... progress to children and adults affected by muscular dystrophy ...
(Date:4/1/2015)... CHICAGO (PRWEB) April 01, 2015 Like ... too is the scientific understanding of the potential causes ... Month by the National Rosacea Society (NRS) to educate ... but treatable facial disorder now estimated to affect more ... long supported medical research on rosacea through its patient-funded ...
(Date:4/1/2015)... IQ Formulations , one of the most highly regarded ... U.S., today is commending GNC for taking steps to boost ... herbal supplements.* GNC vowed that its new processes will look ... labeling on its products. , In response to this ... Jay Cohen said: , “In a lightly-regulated industry where ...
(Date:4/1/2015)... 01, 2015 Health Advocate™, Inc., the ... subsidiary of West Corporation, today launched its new Health ... and through the Health Advocate member website, features ... and stay, healthy. , “We’re pleased to introduce this ... public,” said Martin Rosen, Executive Vice President, Health Advocate. ...
(Date:4/1/2015)... When annoying or concerning skin conditions ... weeks for an appointment with a dermatologist is the ... appointments haven’t been possible within dermatology. However, in the ... noticed demand for this level of service and are ... relief or answers to dermatological issues are to our ...
Breaking Medicine News(10 mins):Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Health Advocate Launches New Health and Wellness Blog 2Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2
... PHILADELPHIA, February 28, 2011 "Honesty is a core ... a breach of that obligation," J. Fred Ralston Jr., ... (ACP) reminded all physicians, including the organization,s 130,000 internal ... ACP,s statement was issued amid reported confusion surrounding "sick ...
... Goodwin HealthDay Reporter , MONDAY, Feb. 28 (HealthDay ... showing the risk of developing Alzheimer,s disease is greater if ... Brain scans of adult children of people with Alzheimer,s found ... had the disease than in those whose fathers had it, ...
... (HealthDay News) -- Heart patients are more likely to survive ... More than 2,800 heart disease patients were given a psychological ... recover from the illness and return to a regular routine. ... Of those deaths, 885 (54 percent) were due to heart ...
... , MONDAY, Feb. 28 (HealthDay News) -- Many American women ... treatment was tied to higher breast cancer risk. A sharp ... after. However, a new study suggests that the 2002-2003 ... continue through 2007. The data suggests that the drop ...
... by Manel Esteller, researcher at Bellvitge Biomedical Research Institute ... by activating the so‑called "dark genome" (or non‑coding DNA) ... the journal Proceedings of the National Academy of ... a genome (the set of our DNA) encoding our ...
... A Wayne State University School of Medicine physician-researcher has ... of cancers. The treatment is based on a naturally ... fool cancer cells into killing themselves. The unique ... on melanoma cells that are resistant to routine treatments ...
Cached Medicine News:Health News:Alzheimer's Risk Looks Higher if Mom Had the Disease 2Health News:Alzheimer's Risk Looks Higher if Mom Had the Disease 3Health News:Drop in Breast Cancer Among White Women May Have Stalled 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: